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Summary The 5T33 multiple myeloma is one of a series of transplantable murine myelomas arising
spontaneously in C57BL/KaLwRij mice. This study describes the establishment and characterisation of the
5T33 murine myeloma in vitro as a cultured cell line in terms of its morphology, growth rate, expression of
paraprotein (IgG2b) and tumorigenicity in syngeneic animals. The 5T33 cell line has been in continuous culture
for over 10 months and has achieved more than passage 34. In culture, 5T33 myeloma grows as single cells or
in small clusters of loosely adherent cells on an adherent stromal cell layer. Maximum doubling time is
approximately 25 h, and over 90% of the cells express cytoplasmic IgG2b paraprotein. The cultured 5T33
myeloma cells are highly tumorigenic in C57BL/KaLwRij mice with as few as 500 cells inducing paralysis and
death as early as day 36 post-tumour inoculation. Kinetics of tumour development and detection of IgG2b
paraprotein are dose dependent. Two weeks following intravenous inoculation of 5 x 105 cultured 5T33
myeloma cells, tumour cells were readily identified in the bone marrow. By 3 weeks post-tumour inoculation,
5T33 myeloma cells were found in various tissues throughout the animal. Studies are now underway to
determine the sensitivity of this cell line to various therapeutic modalities.
Multiple myeloma is a plasma cell malignancy of monoclonal
origin predominantly located in the bone marrow (BM). It is
the most common form of lymphoid malignancy, occurring
primarily in the elderly, and the incidence is increasing (Mell-
stedt et al., 1984; Barlogie et al., 1989). Myeloma cells are
categorised by the degree of differentiation and by growth
pattern in BM, and both of these parameters have been
shown to correlate with prognosis (Bartl et al., 1982; Croese,
1987a). Standard therapy for multiple myeloma consists of
melphalan chemotherapy with or without prednisolone and/
or hemi-body irradiation but even with treatment, median
survival time is only 30-40 months (McElwain & Rowels,
1983; Alexanian & Dreicer, 1984; Kyle et al., 1986; Barlogie
et al., 1987; Hjorth et al., 1990; Barlogie, 1991).
In 1988 Radl et al. described the 5T series of transplan-
table murine multiple myelomas which are remarkably
similar to the human disease. Both the murine and human
myeloma demonstrate progressive monoclonal proliferation,
paraproteinemia (most frequently IgG) which generally in-
creases with tumour progression, and atypical ('myeloma')
plasma cells (Radl et al., 1988). The murine myelomas arose
spontaneously in aged C57BL/KaLwRij mice with a fre-
quency of approximately 0.5% and have been maintained in
vivo by the intravenous (i.v.) transfer of BM cells into
syngeneic recipients (Radl et al., 1988). As an animal model
representative of human multiple myeloma, the 5T series of
transplantable murine myelomas has allowed detailed studies
on the basic biology and histopathology of this malignancy
(Radl et al., 1985; Croese, 1987a; Croese et al., 1987b; Radl
et al., 1988). Initial studies of immunoregulation of multiple
myeloma and response to immunological treatment using
anti-idiotypic monoclonal antibodies have also been per-
formed in the murine model (Croese et al., 1991a, 1991b).
However, the necessity of maintaining these tumours in
animals has limited application of this model, particularly in
assessment of therapeutic efficacy of the numerous chemical
and biological agents currently available for cancer manage-
ment. The time required for tumour growth in animals and
the variability in the kinetics and distribution of tumour
development, dependent upon the number of tumour cells in
the BM transplants, can give rise to major problems in
experimental design and interpretation of results. In addition,
the costs and ethical considerations associated with the use
and maintenance of laboratory animals are of considerable
importance.
The present study describes the establishment and charac-
terisation of the 5T33 murine myeloma in vitro as a cultured
cell line. The morphology and IgG2b paraprotein expression
of cultured 5T33 myeloma cells are essentially identical to
those of the in vivo transplantable tumour in C57BL/
KaLwRij mice described by Radl et al. (1988). In our studies
however, the tumorigenic potential of the cultured cells was
much more constant than that achieved with BM transplants.
With the development of this experimental model of multiple
myeloma as an in vitro cultured cell line and the characterisa-
tion of the tumorigenic potential in syngeneic animals,
detailed studies of the basic biology of this neoplasm and
sensitivity to various therapeutic modalities will be facilitated
whilst minimising animal experimentation.
Materials and methods
Mice
Male and female C57BL/KaLwRij mice, 6-10 weeks old,
were obtained from the Animal Resource Centre (ARC,
Willetton, Australia). Approval of the animal housing facility
and all animal experimental protocols was obtained from the
Animal Experimentation Ethics Committee of Murdoch
University (Western Australia) prior to the initiation of the
project. The 5T33 murine myeloma model was kindly pro-
vided by Dr J. Radl of TNO Institute, Leiden, The Nether-
lands, as a passaged tumour in C57BL/KaLwRij mice. It has
been maintained in syngeneic animals for over 1 year at
Fremantle Hospital by i.v. and intraperitoneal (i.p.) inocula-
tion of 106 cells from ascites or BM in end-stage tumour-
bearing animals.
Establishment of5T33 in vitro as a cultured cell line
The tibiae and femorae of tumour-bearing animals were col-
lected aseptically and single cell suspensions were prepared as
previously described (Croese, 1987a; Croese et al., 1987b).
The BM cells were seeded at high density (5-20 x 106 cells)
into small tissue culture flasks (25 cm3 Costar, Cytosystems,
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Sydney) in 5 ml of Eagles minimal essential medium contain-
ing 10% fetal calf serum (FCS), 2mM L-glutamine, 100 mM
sodium pyruvate, 100 mM non-essential amino acids, 1%
mitoserum (Flow Laboratories, Australian Biosearch, Kar-
rinyup, Australia), 5 x 10-5 M 2-mercaptoethanol (Sigma, St.
Louis, USA) and benzylpenicillin (100,000 units 1`, Com-
monwealth Serum Laboratories, Parkville, Australia). For
the initial establishment of the 5T33 myeloma cells in culture,
107 splenocytes from the same animal were added to the flask
as accessory cells. Additional splenocytes were not required
for the continual growth of the myeloma cells in vitro. The
cells were incubated at 37°C/5% C02/95% humidity and the
medium changed every 3-4 days. After approximately 2
months in culture, the cells were expanded into large flasks
(75 cm3) and have subsequently been maintained by diluting
1:100 with fresh media or by transferring 105 cells into new
flasks every 3-4 days. Aliquots of early passage cells were
frozen in 10% dimethyl sulfoxide/90% FCS and stored in
liquid nitrogen for later reconstitution.
Preparation ofcellsfor morphological and cytological
examination
Morphology of the 5T33 myeloma cells in culture was
studied using an Olympus inverted microscope and photo-
graphed with an Olympus PM-6 Automatic camera using
Kodak TriX pan 400 film.
For cytological examination, cytospin samples (2 drops,
106 cellsml-') were prepared using a Shannon II cytospin
centrifuge (750g, 5 min, Department of Histopathology,
Fremantle Hospital). The slides were immediately fixed in
ethanol and stored at 4°C until used. The cell preparations
were stained with May-Grunwald and examined by light
microscopy.
Determination of5T33 growth rate in culture
To determine the growth rate of 5T33 myeloma cells in
culture, 2.5 x 105 cells were seeded into large tissue culture
flasks in 1Oml of complete medium. Cells were harvested
from duplicate flasks every day for 6 days. Growth rate was
determined using the formula:
T
Doubling time =
(log2 Nf-log2 NS)
T= time in culture
Nf = number of cells at the end of culture
N, = number of cells at the start of culture
Immunofluorescence
Expression of both surface and cytoplasmic IgG2b para-
protein in cultured 5T33 myeloma cells was determined by
standard techniques (Hudson & Hay, 1980) using biotiny-
lated sheep anti-mouse IgG2b (SAMIgG2b, 1:50 dilution,
Alpha Scientific, Langwarrin, Australia) followed by strept-
avidin-fluorescein (1:50 dilution, Amersham Australia,
North Ryde, Australia). The isotype specificity of the
SAMIgG2b was determined by ouchterlony gel diffusion assay
(Serotec). Immunoglobulin-negative thymocytes and B16M
melanoma cells served as negative controls for this reagent
and demonstrated <1% staining.
The number of fluorescing cells was determined using an
Olympus BH-2 fluorescence microscope (200 x magni-
fication). Two hundred cells were counted on four different
preparations for both surface and cytoplasmic fluorescence.
Cells were also assessed by flow cytometry (Coulter Epics
Profile Analyzer; Department of Biomedical Sciences, Curtin
University, Perth, Western Australia) to evaluate possible
differences in surface IgG2b expression as determined by
fluorescence intensity. Five thousand cells were counted in
four different preparations.
Tumorigenicity ofcultured ST33 myeloma cells
Syngeneic C57BL/KaLwRij mice were inoculated with 100,
500, 103, 5 x 103, 104, 105 or 106 cultured 5T33 cells via the
jugular vein or the tail vein. At weekly intervals, blood was
collected from the tail vein into microtainer tubes containing
EDTA (Becton Dickinson, Lane Cove, Australia) and
monitored for IgG2b paraprotein production by agarose gel
electrophoresis (see below). From day 10 onwards, the
animals were examined twice daily for the onset of
paraplegia.
Agarose gel electrophoresis
The 5T33 IgG2b paraprotein was detected using a modified
agarose gel electrophoresis technique (Jeppsson et al., 1979).
Diluted or whole blood samples (1.5pl) were run on a 1%
gel for 45 min at 240 V, < 150 mA, 10°C using a horizontal
electrophoresis unit (Multiphor II, Pharmacia, North Ryde,
Australia). The paraprotein was visualised by Coomassie
Blue staining and quantified by comparison with a standard
curve included on every gel. Protein concentrations between
150 Lg ml-l and 5.0 mg ml-' could be detected using this
method. The paraprotein standard consisted of 5T33 IgG2b
purified from ascites by ammonium sulfate precipitation and
Protein A column chromatography (Hudson & Hay, 1980),
and quantified by spectrophotometry (Novaspec II, Phar-
macia) at 595 nm using a Coomassie protein assay (Pierce,
Rockford, IL, USA).
Kinetics and tissue distribution ofST33 myeloma cells
following intrajugular injection
C57BL/KaLwRij mice were injected with 5 x 105 cultured
5T33 myeloma cells and every week for 5 weeks, three
animals were euthanased and tissues were aseptically col-
lected to determine tumour cell distribution. Single cell
suspensions of the spleen, liver, bone marrow, thymus and
lymph nodes were prepared and examined for the presence of
cytoplasmic IgG2b positive cells as described above. Cytospin
samples were also evaluated cytologically for the presence of
plasma cells. Tissues from one age-matched and sex-matched
control animal were processed at each timepoint to establish
baseline values for each tissue. Blood samples were collected
as described above and differential counts were performed
using a STK-S Coulter Counter (Department of Haema-
tology, Fremantle Hospital) to determine the effect of
tumour progression on blood cell profiles.
Statistical analysis
Data were analysed using the non-paired Student's t-test.
Results
Morphology, growth rate andIgG2b paraprotein expression of
cultured5T33 myeloma cells
The 5T33 myeloma cell line has been in continuous culture
for over 10 months and has achieved over passage 34. In
culture, 5T33 myeloma grows as single cells or in small
clusters of loosely adherent cells on an adherent stromal cell
layer (Figure la). Cytologically, these cells appear as abnor-
mal plasma cells of variable size with a large, highly-granular
nucleus and abundant cytoplasm (Figure lb). Maximum
doubling time of the myeloma cells (passage 15 to passage
20) was 24.9 ± 4.1 h (n = 14). Greater than 90% of the cul-
tured 5T33 cells expressed cytoplasmic IgG2b paraprotein
(Figure lc & d). A much smaller proportion of the cultured
5T33 cells expressed surface IgG2b paraprotein (20.2 ± 1.7%,
n = 6). In general, the amount of IgG2b expressed on the cell
surface as determined by fluorescence intensity was inversely
proportional to cell size (data not shown).1090 L.S. MANNING et al.
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Figure 1 a, Morphology of cultured 5T33 murine myeloma cells taken at passage 18 (magnification = 250 x ). b, Cytology of
cultured 5T33 murine myeloma cells taken at passage 15. Cytospin samples were prepared as described in the Materials and
methods, stained with May-Grunwald stain and examined by light microscopy (magnification = 1250 x ). c & d, Cytoplasmic
IgG2b paraprotein expression of cultured 5T33 murine myeloma cells. Cytoplasmic IgG2b expression was determined by indirect
immunofluorescence as described in Materials and methods. Figure Ic demonstrates specific IgG2b cytoplasmic staining of the
cultured 5T33 myeloma cells compared with background staining shown in Figure Id (magnification = 300 x ).
Tumorigenicity ofcultured 5T33 myeloma cells
Cultured 5T33 myeloma cells were found to be highly
tumorigenic in C57BL/KaLwRij mice with as few as 500 cells
inducing paralysis and death as early as 36 days post-tumour
inoculation (Figure 2). Survival time was directly related to
tumour cell number. All of the animals injected with over 104
cells developed paraprotein and paralysis resulting in death
by day 50 post-tumour inoculation, whereas none of the
animals injected with 100 cells showed any sign of disease by
day 80 (Figure 2). No difference in tumour development was
observed when tumour inoculation was performed via tail
vein or jugular vein. The mean survival time of animals
inoculated intrajugularly with 105 5T33 myeloma cells was
37.7 ± 2.3 days compared with 39.0 ± 3.1 days for animals
inoculated via the tail vein (P = NS). Paraprotein was
detected 7-14 days prior to the onset of paralysis and in-
creased with increasing tumour burden to a maximum of
approximately 30 mg ml- regardless of the initial cell dose
(see below).
Kinetics and tissue distribution ofcultured 5T33 myeloma cells
Within two weeks of i.v. inoculation of 5 x 105 cultured 5T33
myeloma cells, a significant increase in the number of cyto-
plasmic IgG2b positive cells was observed in the liver and
bone marrow of tumour-bearing animals compared with con-
trols (P<0.01, Figure 3, Table I). By day 21, all tissues
examined demonstrated a large increase in cytoplasmic IgG2b
positive cells when compared with control tissues (P<0.01).
The increased tumour cell population in the spleen and liver
occurred in parallel with a significant increase in the size and
weight of these two tissues (P<0.01; Figure 4). The propor-
tion of tumour cells in the various tissues continued to
increase with time, particularly in the liver and bone marrow
where, by week 5, over 70% of the isolated cells were
positive for cytoplasmic IgG2b. Similar liver, spleen and bone
marrow involvement was observed when bone marrow cells
from end-stage 5T33-bearing mice were used as the inoculum
(data not shown).
Cytological evaluation ofplasma cells in the various tissues
demonstrated a similar pattern of tumour cell kinetics and
distribution (Table I). Approximately 70% of the nucleated
cells isolated from the blood of tumour-bearing animals at
week 5 were positive for cytoplasmic IgG2b compared with
7.9 ± 4.3% in control animals (n = 9, data not shown). IgG2b
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Figure 2 Effect of 5T33 myeloma cell concentration on survival
of C57BL/KaLwRij mice. Groups of 6-13 female mice were
injected i.v. with 100 (A), 500 (0), 103 (-), 5 X 103 (O), 104
(O), 105 (*) or 106 (El) cultured 5T33 myeloma cells and
monitored on a daily basis for the onset of paralysis. The data
are presented as the percentage of animals surviving in each
group with time (days) post-tumour inoculation.
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Table I Tissue distribution of 5T33 myeloma cells following intrajugular inoculation
Weeks post-tumour inoculation
0 1 2 3 4 5
Percentage cytoplasmic IgG2b positive cells ( s.d.)
I. Immunofluorescence
Thymus <1 <1 3.6±0.5* 5.5±2.1* 16.3±2.3* 26.2± 1.7*
Lymph-nodes 19.1 + 2.1 21.7 ± 3.7 21.8 ± 4.2 31.3 4.7* 37.1 3.9* 34.2 ± 5.0*
Spleen 25.3 ± 2.3 28.5 ± 2.3 25.5 ± 2.7 51.2 ± 5.6* 64.1 4.7* 57.9 ± 2.8*
Liver 4.2 ± 1.8 10.6 + 2.0 19.0 ± 2.0* 54.0 3.7* 77.6 ± 3.0* 74.9 ± 4.1*
Bone Marrow 4.5 ± 1.8 7.6 2.5 16.6 2.7* 64.2 1.0* 63.1 3.4* 71.1 ±4.6*
II. Cytology
Thymus <1 3.3+0.8 2.0±0.5 1.0±0.0 12.8±2.5 8.5±2.5
Lymph-nodes <1 2.0 0.4 2.0 0.5 2.5 0.8 15.3 2.5* 11.0 2.1*
Spleen <5 4.5±0.6 5.7± 1.7 70.0±4.9* 71.8±4.0* 71.5±4.1*
Liver <1 1.0 0.0 8.3 ± 0.8* 46.0 3.6* 52.0 2.9* 42.5 3.5*
Bone Marrow <1 2.5 ± 0.8 13.3 ± 1.4* 73.0 3.4* 78.8 4.9* 85.0 5.7*
Cytoplasmic IgG2b positive cells and plasma cells were identified as described in the Materials and
methods. The data are presented as the mean (± s.d.) for 3-6 animals for each time point.
*P<0.05 comparing thepercentageofcytoplasmic IgG2bpositivecellsandplasmacells to baseline(week0)
values.
paraprotein was first detected in the blood between day 14
and day 21 post-tumour inoculation and increased signi-
ficantly to a maximum of 30 mg ml' by day 28 (Figure 5).
Alterations in normal blood cell profiles occurred in
parallel with tumour progression. A significant elevation in
platelet number was observed at day 7 post-tumour inocula-
tion but by day 21, the cell populations of platelets, red
blood cells and white blood cells were significantly reduced
and remained low throughout the 5 week observation period
(P<0.01; Figure 6).
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Figure 3 Tissue distribution of 5T33 myeloma cells following
intrajugular injection of 5 x 105 cells. The data are presented as
the mean ( ± s.d.) percent IgG2b cytoplasmic positive cells for
3-6 animals for each time point.
Discussion
The 5T33 murine myeloma model is one of several multiple
myelomas which arose spontaneously in aged C57BL/
KaLwRij mice (Radl et al., 1988). These tumours have been
maintained by transplantation into syngeneic recipients and
have been used for detailed studies on several aspects of the
biology, histopathology and immunoregulation of myeloma
(Radl et al., 1985, 1988; Croese, 1987a; Croese et al., 1987b;
Croese et al., 1991a, 1991b). These murine myelomas are
remarkably similar to human multiple myeloma, and many
of the findings may have direct clinical application.
Although this experimental animal model has proven
invaluable for the in vivo study of myeloma, investigations
have been limited by the lack of an in vitro cell line counter-
part for this series of transplantable tumours. In particular,
initial assessments of growth factor production and require-
ments for myeloma development cannot be evaluated in vivo
or in short term in vitro cultures. Similarly, efficacy of the
extensive range of chemical and biological agents now
available for cancer therapy cannot be adequately assessed in
an in vivo model due to the time and number of animals
required to evaluate responses. We have established the 5T33
myeloma as an in vitro cultured cell line and characterised it
in vivo to facilitate such studies.
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Figure 4 Effect of 5T33 myeloma progression on liver and
spleen weights. Mice were inoculated with 5T33 cultured
myeloma cells as described in Figure 3. At weekly intervals, the
liver and spleen were collected from at least three animals and
weighed. The data is presented as the mean weight in grams
( ± s.d.) of the spleen and liver for 3-6 mice for each time point.
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Figure 5 IgG2b paraprotein development with 5T33 tumour pro-
gression. Mice were inoculated with 5 x 105 5T33 cultured
myeloma cells by intrajugular injection. At weekly intervals,
blood was collected and analysed for IgG2b paraprotein by
agarose gel electrophoresis (Materials and methods). The data are
presented as the mean paraprotein concentration in milligrams
ml-' (± s.d.) for 3-6 mice for each time point.
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5T33 myeloma progression on blood cell
Early studies in our laboratory comparing the cultured
5T33 myeloma cells to those isolated from in vivo passaged
tumours found the cells to be indistinguishable with respect
to cytology and IgG2b paraprotein expression, and both
parameters were consistent with the original description of
the spontaneous tumour (Radl et al., 1988). The mor-
phological heterogeneity and variability in surface para-
protein expression which we observed in cultured 5T33
myeloma cells have also been described for the transplantable
5T2 multiple myeloma model where such heterogeneity was
found to reflect different stages of differentiation (Croese,
1987a; Croese et al., 1987b). This morphological hetero-
geneity of the 5T33 cultured cells may also explain the
differences observed between the detection of cytoplasmic
IgG2b positive cells by immunofluorescence and the cyto-
logical evaluation of plasma cells following 5T33 tumour
inoculation (Table I). The smaller 5T33 myeloma cells were
found to be intensely positive for the IgG2b paraprotein and
yet did not appear cytologically as plasma cells. Conversely,
the small percentage (< 10%) of 5T33 cells which were
negative for cytoplasmic IgG2b were primarily of the larger
'plasma cell'-like population. Clonal analysis of the cultured
5T33 cells may help delineate the various precursor popula-
tions involved in myeloma development in terms of
phenotype, proliferation potential, growth requirements and
functional activities.
Tumorigenic potential of the cultured 5T33 myeloma cells
is similar to the in vivo passaged tumour but, in our hands,
paraprotein production, onset of paraplegia and survival time
are much more consistent and reproducible when using cul-
tured 5T33 cells than when using BM cells from tumour-
bearing animals. This is probably due both to selection
pressure of in vitro culture conditions on tumour subpopula-
tions and to the variable number of tumour cells present in
the BM of end-stage animals. We have shown in this study
that the kinetics of 5T33 myeloma progression and tissue
distribution in vivo are directly related to tumour cell dose. In
addition, as few as 500 myeloma cells were found to be
sufficient to induce malignancy which has important implica-
tions for clinical procedures utilising purged autologous bone
marrow transplantation for the treatment of multiple
myeloma. Based on this experimental evidence, purging pro-
cedures would have to achieve a bone marrow preparation
containing less than 500 tumour cells to minimise re-
crudescence.
The extensive liver, spleen and bone marrow involvement
observed during 5T33 tumour progression occurred whether
using cultured 5T33 myeloma cells or in vivo passaged bone
marrow cells as the inoculum. Spleen and bone marrow
involvement has also been found for the 5T2 myeloma, but
no liver involvement was described for this subline (Radl et
al., 1988). In our animals, liver involvement with 5T2 and
5T7 myeloma was not observed (unpublished data). The
5T33 myeloma did however involve the liver and may repre-
sent a different tumour type of myeloma. In the human
disease, the type of myeloma has important implications in
terms of prognosis and responsiveness to therapy (Croese,
1987a; Bartl et al., 1982).
With the establishment of the 5T33 myeloma model as a
cultured cell line, animals are no longer required for in vivo
tumour maintenance thereby reducing animal use to direct
experimental procedures. In addition, the development of this
cultured cell line now allows a more detailed evaluation of
myeloma cell susceptibility to a wide range of chemo-
therapeutic drugs and biological response modifiers. In vitro
sensitivity studies using both human and animal tumour cell
lines have been shown to be predictive of patient respon-
siveness, particularly in determining tumour resistance (van
Hoff, 1990). The predictive value of in vitro sensitivity testing
allows a systematic assessment of therapeutic options thereby
providing a rational basis for treatment selection without
placing patients at risk. Preliminary studies are underway
using the cultured 5T33 myeloma cell line to evaluate the in
vitro and in vivo susceptibility of this cell type to various
forms of therapy including melphalan chemotherapy, internal
radionuclide therapy using '53Samarium-ethylene-diamine-
tetramethylene phosphonate, and immunotherapy using
cytokines such as the interferons alpha, beta and gamma,
tumour necrosis factor and the interleukins 1, 2 4, & 6.
The 5T33 cell line appears to be the first of this series of
seven murine myelomas which does not require IL-6 for
short- or long-term growth in culture (Dr J. Radl and Dr R.
Mundy, personal communication). Other differences in
growth factor production and/or requirements of myeloma
cells are currently being evaluated using the cultured 5T33
cell line and early passages of 5T2 and 5T7 myeloma cells.
Such differences may correlate with the degree of
differentiation and pattern of growth in the bone marrow
and therefore could be of direct clinical relevance. Col-
laborative studies have also been initiated to examine altera-
tions in oncogene expression of the murine myeloma cell
lines compared with that of their human counterparts.
Transplantable murine myeloma lines have allowed
detailed study of the biology and histopathology of this type
of malignancy. It is anticipated that our establishment of a
well-characterised cultured cell line of 5T33 murine myeloma
will provide specific information on growth factor require-
ments, therapeutic susceptibility and genetic alterations in-
herent in myeloma development with the potential for direct
application to human multiple myeloma.
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